APA (7th ed.) Citation

Hosseini, I., Gadkar, K., Stefanich, E., Li, C., Sun, L. L., Chu, Y., & Ramanujan, S. (2020). Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: Impact of translational system modeling. NPJ systems biology and applications, 6(1), 28. https://doi.org/10.1038/s41540-020-00145-7

Chicago Style (17th ed.) Citation

Hosseini, Iraj, Kapil Gadkar, Eric Stefanich, Chi-Chung Li, Liping L. Sun, Yu-Waye Chu, and Saroja Ramanujan. "Mitigating the Risk of Cytokine Release Syndrome in a Phase I Trial of CD20/CD3 Bispecific Antibody Mosunetuzumab in NHL: Impact of Translational System Modeling." NPJ Systems Biology and Applications 6, no. 1 (2020): 28. https://doi.org/10.1038/s41540-020-00145-7.

MLA (9th ed.) Citation

Hosseini, Iraj, et al. "Mitigating the Risk of Cytokine Release Syndrome in a Phase I Trial of CD20/CD3 Bispecific Antibody Mosunetuzumab in NHL: Impact of Translational System Modeling." NPJ Systems Biology and Applications, vol. 6, no. 1, 2020, p. 28, https://doi.org/10.1038/s41540-020-00145-7.